AWM
CYTK icon

AE Wealth Management’s Cytokinetics CYTK Stock Holding History

AE Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
5,316
+1,011
+23% +$72.6K ﹤0.01% 1266
2026
Q1 		$284K Buy
4,305
+909
+27% +$57.8K ﹤0.01% 1410
2025
Q4 		$216K Buy
+3,396
New +$211K ﹤0.01% 1486

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AE Wealth Management's CYTK Position: Q2 2026 in Review

AE Wealth Management increased its Cytokinetics (CYTK) stake by 23% in Q2 2026, buying an estimated $72.6K and bringing the position to 5,316 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

AE Wealth Management first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • AE Wealth Management held 5,316 shares of Cytokinetics worth $453K as of Q2 2026.
  • AE Wealth Management bought 1,011 Cytokinetics shares in Q2 2026, an estimated $72.6K.
  • Cytokinetics made up ﹤0.01% of AE Wealth Management's portfolio in Q2 2026, its #1266 holding.
  • AE Wealth Management first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.